NASDAQ: ZBIO
Zenas Biopharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for ZBIO

Based on 6 analysts offering 12 month price targets for Zenas Biopharma Inc

Min Forecast
$19.00+166.11%
Avg Forecast
$31.83+345.84%
Max Forecast
$45.00+530.25%

Should I buy or sell ZBIO stock?

Based on 6 analysts offering ratings for Zenas Biopharma Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ZBIO's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ZBIO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their ZBIO stock forecasts and price targets.

ZBIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-02-04
lockedlocked$00.00+00.00%2024-12-16
lockedlocked$00.00+00.00%2024-12-11
lockedlocked$00.00+00.00%2024-10-08
lockedlocked$00.00+00.00%2024-10-08
Guggenheim
Top 42%
59
Strong BuyInitiates Coverage On$45.00+530.25%2024-10-08

1 of 1

Forecast return on equity

Is ZBIO forecast to generate an efficient return?

Company
-28.6%
Industry
153.23%
Market
88.87%
ZBIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ZBIO forecast to generate an efficient return on assets?

Company
-25.48%
Industry
34.91%
ZBIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ZBIO earnings per share forecast

What is ZBIO's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$3.50
Avg 2 year Forecast
-$3.02
Avg 3 year Forecast
-$3.16

ZBIO revenue forecast

What is ZBIO's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$48.6M
Avg 2 year Forecast
$38.9M
Avg 3 year Forecast
$84.4M

ZBIO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ZBIO$7.14$31.83+345.84%Strong Buy
GOSS$1.31$10.00+663.36%Buy
MBX$8.99$37.25+314.35%Strong Buy
ALLO$1.41$9.00+538.30%Strong Buy
ATYR$3.59$19.25+436.21%Strong Buy

Zenas Biopharma Stock Forecast FAQ

Is Zenas Biopharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ZBIO) stock is to Strong Buy ZBIO stock.

Out of 6 analysts, 4 (66.67%) are recommending ZBIO as a Strong Buy, 2 (33.33%) are recommending ZBIO as a Buy, 0 (0%) are recommending ZBIO as a Hold, 0 (0%) are recommending ZBIO as a Sell, and 0 (0%) are recommending ZBIO as a Strong Sell.

If you're new to stock investing, here's how to buy Zenas Biopharma stock.

What is ZBIO's earnings growth forecast for 2025-2027?

(NASDAQ: ZBIO) Zenas Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.72%.

Zenas Biopharma's earnings in 2025 is N/A.On average, 3 Wall Street analysts forecast ZBIO's earnings for 2025 to be -$146,406,540, with the lowest ZBIO earnings forecast at -$155,044,747, and the highest ZBIO earnings forecast at -$131,641,767. On average, 3 Wall Street analysts forecast ZBIO's earnings for 2026 to be -$126,071,021, with the lowest ZBIO earnings forecast at -$151,283,554, and the highest ZBIO earnings forecast at -$101,970,130.

In 2027, ZBIO is forecast to generate -$132,059,677 in earnings, with the lowest earnings forecast at -$155,044,747 and the highest earnings forecast at -$109,074,607.

What is ZBIO's revenue growth forecast for 2026-2028?

(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.72%.

Zenas Biopharma's revenue in 2025 is N/A.On average, 2 Wall Street analysts forecast ZBIO's revenue for 2026 to be $2,031,880,219, with the lowest ZBIO revenue forecast at $511,522,293, and the highest ZBIO revenue forecast at $3,552,238,145. On average, 2 Wall Street analysts forecast ZBIO's revenue for 2027 to be $1,627,342,981, with the lowest ZBIO revenue forecast at $1,433,432,569, and the highest ZBIO revenue forecast at $1,821,253,392.

In 2028, ZBIO is forecast to generate $3,528,417,254 in revenue, with the lowest revenue forecast at $3,105,074,049 and the highest revenue forecast at $3,951,760,459.

What is ZBIO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ZBIO) forecast ROA is -25.48%, which is lower than the forecast US Biotechnology industry average of 34.91%.

What is ZBIO's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ZBIO price target, the average ZBIO price target is $31.83, with the highest ZBIO stock price forecast at $45.00 and the lowest ZBIO stock price forecast at $19.00.

On average, Wall Street analysts predict that Zenas Biopharma's share price could reach $31.83 by Feb 4, 2026. The average Zenas Biopharma stock price prediction forecasts a potential upside of 345.84% from the current ZBIO share price of $7.14.

What is ZBIO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ZBIO) Zenas Biopharma's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that ZBIO's EPS will be -$3.50 for 2025, with the lowest EPS forecast at -$3.71, and the highest EPS forecast at -$3.15. On average, analysts forecast that ZBIO's EPS will be -$3.02 for 2026, with the lowest EPS forecast at -$3.62, and the highest EPS forecast at -$2.44. In 2027, ZBIO's EPS is forecast to hit -$3.16 (min: -$3.71, max: -$2.61).

What is ZBIO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ZBIO) forecast ROE is -28.6%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.